Key result
Edoxaban 60 mg daily is an effective and safe alternative to warfarin for preventing thromboembolic complications in patients with nonvalvular atrial fibrillation.
Why the study?
Does edoxaban prevent thromboembolic complications in patients with nonvalvular atrial fibrillation?
Population
Patients with nonvalvular atrial fibrillation
Comparison
Edoxaban vs warfarin
Design
Review
Authors
Loading...
Supports edoxaban to simplify anticoagulation without INR monitoring in nonvalvular AF; confirms randomized evidence favoring NOACs.
Does edoxaban prevent thromboembolic complications in patients with nonvalvular atrial fibrillation?
Edoxaban is an effective, safe, and convenient direct oral anticoagulant for stroke prevention in nonvalvular atrial fibrillation, including in complex clinical scenarios such as concomitant ischemic heart disease or percutaneous coronary interventions.
О. О. Шахматова (2020) conducted a review in Atrial fibrillation. Edoxaban vs. Warfarin was evaluated. Edoxaban 60 mg daily is an effective and safe alternative to warfarin for preventing thromboembolic complications in patients with nonvalvular atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: